Stable corticosteroid nanoparticulate formulations and methods for the making and use thereof

1. A pharmaceutical formulation of stabilized corticosteroid particles, comprising a corticosteroid, a hydrophilic polymer, a wetting agent selected from the group consisting of sodium lauryl sulfate, a pharmaceutically acceptable salt of docusate, Tween 20, Tween 80 and mixtures thereof, and an effective amount of a complexing agent that stabilizes particle growth after an initial particle growth and endpoint is reached, the complexing agent consisting of at least one paraben or a pharmaceutically acceptable salt thereof, wherein the stabilized particles have a volume weighted median diameter (D50) of the particles from about 50 nm to about 500 nm, and wherein said pharmaceutical formulation is suitable for administration intranasally or via inhalation.

2. The pharmaceutical formulation of claim 1 , which is in the form of an aqueous dispersion containing the particles in from about 0.1% to about 0.9% saline.

3. The pharmaceutical formulation of claim 1 suitable for inhalation administration, consisting of the particles suspended in a nebulizing media.

4. The pharmaceutical formulation of claim 1 , suitable for inhalation administration, consisting of the particles in dry form.

5. The pharmaceutical formulation of claim 1 , wherein the complexing agent is present in an amount from about 0.005 to about 40% w/w, based on the weight of the particles.

6. The pharmaceutical formulation of claim 1 , wherein the at least one paraben is selected from the group consisting of methylparaben, ethylparaben, propylparaben, pharmaceutically acceptable salts thereof and mixtures thereof.

7. The pharmaceutical formulation of claim 1 , wherein the hydrophilic polymer is selected from the group consisting of a cellulosic polymer, a vinyl polymer and mixtures thereof.

8. The pharmaceutical formulation of claim 1 , wherein the hydrophilic polymer comprises a cellulosic polymer.

9. The pharmaceutical formulation of claim 1 , wherein the hydrophilic polymer is a cellulose ether.

10. The pharmaceutical formulation of claim 1 , wherein the hydrophilic polymer is hydroxypropylmethylcellulose.

11. The pharmaceutical formulation of claim 1 , wherein the hydrophilic polymer is a vinyl polymer.

12. The pharmaceutical formulation of claim 1 , wherein the hydrophilic polymer is a polyvinyl alcohol.

13. The pharmaceutical formulation of claim 1 , wherein the corticosteroid is selected from the group consisting of budesonide, triamcinolone acetonide, triamcinolone, mometasone, mometasone furoate anhydrous, flunisolide, fluticasone propionate, fluticasone, beclomethasone dipropionate, dexamethasone, triamincinolone, beclomethasone, fluocinolone, fluocinonide, flunisolide hemihydrate, mometasone furoate monohydrate, clobetasol, and pharmaceutically acceptable salts, hydrates, polymorphs and combinations thereof.

14. The pharmaceutical formulation of claim 1 , wherein the corticosteroid is selected from the group consisting of mometasone, mometasone furoate anhydrous, mometasone furoate monohydrate and pharmaceutically acceptable salts, hydrates, polymorphs and combinations thereof.

15. The pharmaceutical formulation of claim 1 , wherein a single dose of intranasal suspension provides a therapeutically effective amount of the corticosteroid that is about ⅓to about ½the dose required to achieve therapeutic efficacy as compared to an intranasal suspension with particle size >1 micron containing the same corticosteroid.

16. Complexed stabilized corticosteroid particles, comprising particles of a corticosteroid together with an effective amount of a complexing agent that stabilizes particle growth, the complexing agent consisting of at least one paraben or a pharmaceutically acceptable salt thereof, a hydrophilic polymer, and a wetting agent selected from the group consisting of sodium lauryl sulfate, a pharmaceutically acceptable salt of docusate, Tween 20, Tween 80 and mixtures thereof, wherein the stabilized particles have a volume weighted median diameter (D50) of the particles from about 50 nm to about 500 nm, and wherein said particles are suitable for administration intranasally or via inhalation.

17. The complexed stabilized corticosteroid particles of claim 16 , wherein the at least one paraben is selected from the group consisting of methylparaben, ethylparaben, propylparaben, pharmaceutically acceptable salts thereof and mixtures thereof.

18. The complexed stabilized corticosteroid particles of claim 16 , suitable for inhalation administration, consisting of the particles suspended in a nebulizing media.

19. The complexed stabilized corticosteroid particles of claim 16 , suitable for inhalation administration, consisting of the particles in dry form.

20. The complexed stabilized corticosteroid particles of claim 16 , wherein the complexing agent is present in an amount from about 0.005 to about 40% w/w, based on the weight of the particles.

21. The complexed stabilized corticosteroid particles of claim 16 , wherein the corticosteroid is selected from the group consisting of budesonide, triamcinolone acetonide, triamcinolone, mometasone, mometasone furoate anhydrous, flunisolide, fluticasone propionate, fluticasone, beclomethasone dipropionate, dexamethasone, triamincinolone, beclomethasone, fluocinolone, fluocinonide, flunisolide hemihydrate, mometasone furoate monohydrate, clobetasol, and pharmaceutically acceptable salts, hydrates, polymorphs and combinations thereof.

22. The complexed stabilized corticosteroid particles of claim 16 , wherein the corticosteroid is mometasone, mometasone furoate anhydrous, mometasone furoate monohydrate and pharmaceutically acceptable salts, hydrates, polymorphs and combinations thereof.

23. An aqueous nanosuspension of complexed stabilized corticosteroid particles, comprising complexed stabilized particles of a corticosteroid together with an effective amount of a complexing agent that stabilizes particle growth, a hydrophilic polymer, and a wetting agent, the complexing agent consisting of at least one paraben or a pharmaceutically acceptable salt thereof, the group consisting of sodium lauryl sulfate, a pharmaceutically acceptable salt of docusate, Tween 20, Tween 80 and mixtures thereof, wherein the complexed stabilized corticosteroid particles have a volume weighted median diameter (D50) of the particles from about 50 nm to about 500 nm, and wherein said nanosuspension is suitable for intranasal administration, the nanosuspension further comprising one or more excipients sleeted from the group consisting of a suspending agent, a humectant, a buffer, a surfactant, an antimicrobial preservative, and mixtures of any of the foregoing.

24. The aqueous nanosuspension of claim 23 , wherein the complexed stabilized corticosteroid particles are suspended in from about 0.1% to about 0.9% saline.

25. The aqueous nanosuspension of claim 24 , further comprising an effective amount of an antimicrobial preservative.

26. The aqueous nanosuspension of claim 23 , wherein the at least one paraben is selected from the group consisting of methylparaben, ethylparaben, propylparaben, pharmaceutically acceptable salts thereof and mixtures thereof.

27. The pharmaceutical formulation of claim 1 , further comprising benzoic acid, phenol, methyl anthranilate, pharmaceutically acceptable salts thereof, or mixtures thereof.

28. The complexed stabilized corticosteroid particles of claim 16 , further comprising phenol, benzoic acid, methyl anthranilate, pharmaceutically acceptable salts thereof, or mixtures thereof.